LPAR1 and cancer: While our primary focus was on the role of LPAR1 as a glutamate metabolic regulator in TC-anlotinib resistance, it is also possible that the MAPK pathway contributes to resistance, given its established association with chemotherapy resistance in various malignant tumors.